SAB Biotherapeutics Inc

NEW
NAS:SABS (USA)  
$ 3.26 +0.15 (+4.82%) 04:00 PM EST
At Loss
P/B:
0.64
Market Cap:
$ 30.09M
Enterprise V:
$ -2.36M
Volume:
105.97K
Avg Vol (2M):
77.21K
Trade In:
Volume:
105.97K
At Loss
Avg Vol (2M):
77.21K

Business Description

SAB Biotherapeutics Inc
NAICS : 541714 SIC : 2834
ISIN : US78397T2024
Description
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Name Current Vs Industry Vs History
Cash-To-Debt 6.99
Equity-to-Asset 0.75
Debt-to-Equity 0.12
Debt-to-EBITDA -0.15
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 74.15
9-Day RSI 64.87
14-Day RSI 60.25
6-1 Month Momentum % -37.06
12-1 Month Momentum % -73.13

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.24
Quick Ratio 5.24
Cash Ratio 4.94

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -28.5
Shareholder Yield % 0.63

Financials (Next Earnings Date:2024-11-13 Est.)

SABS's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SABS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

SAB Biotherapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -6.17
Beta 0.87
Volatility % 87.13
14-Day RSI 60.25
14-Day ATR ($) 0.271525
20-Day SMA ($) 2.750505
12-1 Month Momentum % -73.13
52-Week Range ($) 2.16 - 10
Shares Outstanding (Mil) 9.23

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

SAB Biotherapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

SAB Biotherapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

SAB Biotherapeutics Inc Frequently Asked Questions

What is SAB Biotherapeutics Inc(SABS)'s stock price today?
The current price of SABS is $3.26. The 52 week high of SABS is $10.00 and 52 week low is $2.16.
When is next earnings date of SAB Biotherapeutics Inc(SABS)?
The next earnings date of SAB Biotherapeutics Inc(SABS) is 2024-11-13 Est..
Does SAB Biotherapeutics Inc(SABS) pay dividends? If so, how much?
SAB Biotherapeutics Inc(SABS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1